NO20015462L - Anvendelse av fthalazinderivater - Google Patents

Anvendelse av fthalazinderivater

Info

Publication number: NO20015462L
Authority: NO; Norway
Prior art keywords: phthalazine derivatives; parp; inhibitors; homologous enzymes; phthalazine
Prior art date: 1999-05-11

Application number

NO20015462A

Other languages

English (en)

Norwegian (no)

Other versions

NO20015462D0 (no

Inventor

Wilfried Lubisch

Jens Sadowski

Michael Kock

Thomas Hoeger

Original Assignee

Basf Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-05-11

Filing date

2001-11-08

Publication date

2001-11-08

2001-11-08 Application filed by Basf Ag filed Critical Basf Ag

2001-11-08 Publication of NO20015462D0 publication Critical patent/NO20015462D0/no

2001-11-08 Publication of NO20015462L publication Critical patent/NO20015462L/no

Links

LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical class C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 title abstract 3
108090000790 Enzymes Proteins 0.000 abstract 2
102000004190 Enzymes Human genes 0.000 abstract 2
102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 abstract 2
239000003112 inhibitor Substances 0.000 abstract 2
102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 abstract 1
108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 abstract 1
229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Psychology (AREA)
Dermatology (AREA)
Communicable Diseases (AREA)
Immunology (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Physical Education & Sports Medicine (AREA)
Surgery (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Compositions Of Macromolecular Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

NO20015462A 1999-05-11 2001-11-08 Anvendelse av fthalazinderivater NO20015462L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19921567A DE19921567A1 (de)	1999-05-11	1999-05-11	Verwendung von Phthalazine-Derivaten
PCT/EP2000/003967 WO2000067734A2 (fr)	1999-05-11	2000-05-03	Utilisation de derives de phtalazine

Publications (2)

Publication Number	Publication Date
NO20015462D0 NO20015462D0 (no)	2001-11-08
NO20015462L true NO20015462L (no)	2001-11-08

Family

ID=7907632

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20015462A NO20015462L (no)	1999-05-11	2001-11-08	Anvendelse av fthalazinderivater

Country Status (20)

Country	Link
US (1)	US6903098B1 (fr)
EP (1)	EP1231982B1 (fr)
JP (1)	JP2003502286A (fr)
KR (1)	KR20020000642A (fr)
CN (1)	CN1399573A (fr)
AT (1)	ATE357272T1 (fr)
AU (1)	AU5064000A (fr)
BG (1)	BG106056A (fr)
BR (1)	BR0010428A (fr)
CA (1)	CA2372704A1 (fr)
CZ (1)	CZ20014038A3 (fr)
DE (2)	DE19921567A1 (fr)
ES (1)	ES2284499T3 (fr)
HU (1)	HUP0202477A3 (fr)
IL (1)	IL146148A0 (fr)
NO (1)	NO20015462L (fr)
PL (1)	PL352150A1 (fr)
SK (1)	SK286676B6 (fr)
TR (1)	TR200103236T2 (fr)
WO (1)	WO2000067734A2 (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6291425B1 (en)	1999-09-01	2001-09-18	Guilford Pharmaceuticals Inc.	Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
EP1223932A4 (fr) *	1999-10-01	2003-01-15	Smithkline Beecham Corp	Composes et methodes
JP2003528073A (ja) *	2000-03-20	2003-09-24	エヌ・ジーンリサーチラボラトリーズインコーポレイテッド	プロペンカルボン酸アミドキシム誘導体、その製法、及びこの誘導体を含有する医薬組成物
US7151102B2 (en)	2000-10-30	2006-12-19	Kudos Pharmaceuticals Limited	Phthalazinone derivatives
KR100957516B1 (ko) *	2001-08-15	2010-05-14	이코스 코포레이션	2ｈ-프탈라진-1-온 및 이것의 사용 방법
DE60335359D1 (de)	2002-04-30	2011-01-27	Kudos Pharm Ltd	Phthalazinonderivate
ATE405658T1 (de)	2002-07-26	2008-09-15	Basf Plant Science Gmbh	Neue selektionsverfahren
CN100390164C (zh)	2002-10-01	2008-05-28	三菱制药株式会社	异喹啉化合物及其医药用途
ATE540928T1 (de)	2002-11-22	2012-01-15	Mitsubishi Tanabe Pharma Corp	Isochinolinverbindungen und ihre medizinische verwendung
US7449464B2 (en)	2003-03-12	2008-11-11	Kudos Pharmaceuticals Limited	Phthalazinone derivatives
GB0305681D0 (en)	2003-03-12	2003-04-16	Kudos Pharm Ltd	Phthalazinone derivatives
GB0419072D0 (en)	2004-08-26	2004-09-29	Kudos Pharm Ltd	Phthalazinone derivatives
EP2166102B1 (fr)	2005-03-08	2012-12-19	BASF Plant Science GmbH	Expression à amélioration de séquences d'intron
EP1906948A4 (fr) *	2005-07-18	2010-03-17	Bipar Sciences Inc	Traitement du cancer
GB0521373D0 (en)	2005-10-20	2005-11-30	Kudos Pharm Ltd	Pthalazinone derivatives
US20100279327A1 (en) *	2006-06-12	2010-11-04	Bipar Sciences, Inc.	Method of treating diseases with parp inhibitors
US20080262062A1 (en) *	2006-11-20	2008-10-23	Bipar Sciences, Inc.	Method of treating diseases with parp inhibitors
CA2655257A1 (fr) *	2006-06-12	2008-12-04	Bipar Sciences, Inc.	Procede permettant de traiter des maladies avec des inhibiteurs de parp
AU2007292306A1 (en) *	2006-09-05	2008-03-13	Bipar Sciences, Inc.	Inhibition of fatty acid synthesis by PARP inhibitors and methods of treatment thereof
WO2008030883A2 (fr) *	2006-09-05	2008-03-13	Bipar Sciences, Inc.	Traitement du cancer
UY30639A1 (es)	2006-10-17	2008-05-31	Kudos Pharm Ltd	Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
US8466150B2 (en)	2006-12-28	2013-06-18	Abbott Laboratories	Inhibitors of poly(ADP-ribose)polymerase
MX347085B (es) *	2006-12-28	2017-04-06	Abbott Laboratories *	Inhibidores de la poli (adp-ribosa) polimerasa.
US20090023727A1 (en) *	2007-07-05	2009-01-22	Muhammad Hashim Javaid	Phthalazinone derivatives
WO2009034326A1 (fr)	2007-09-14	2009-03-19	Astrazeneca Ab	Dérivés de phtalazinone
AU2008321382A1 (en) *	2007-11-12	2009-05-22	Bipar Sciences, Inc.	Treatment of uterine cancer and ovarian cancer with a PARP inhibitor alone or in combination with anti-tumor agents
WO2009064738A2 (fr) *	2007-11-12	2009-05-22	Bipar Sciences, Inc.	Traitement de cancer du sein avec un inhibiteur parp seul ou en combinaison avec des agents anti-tumoraux
AU2008333786A1 (en) *	2007-12-07	2009-06-11	Bipar Sciences, Inc.	Treatment of cancer with combinations of topoisomerase inhibitors and PARP inhibitors
AR070221A1 (es)	2008-01-23	2010-03-25	Astrazeneca Ab	Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
CA2713156A1 (fr) *	2008-02-04	2009-08-13	Bipar Sciences, Inc.	Procedes de diagnostic et de traitement de maladies mediees par parp
HUE035295T2 (en)	2008-08-06	2018-05-02	Medivation Technologies Inc	Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
EP2346495B2 (fr)	2008-10-07	2023-05-24	Kudos Pharmaceuticals Limited	Formulation pharmaceutique 514
CN102725412B (zh)	2009-11-27	2017-09-22	巴斯夫植物科学有限公司	优化的内切核酸酶及其用途
AU2010325563B2 (en)	2009-11-27	2017-02-02	Basf Plant Science Company Gmbh	Chimeric endonucleases and uses thereof
WO2011064751A1 (fr)	2009-11-27	2011-06-03	Basf Plant Science Company Gmbh	Endonucléases chimériques et utilisations de celles-ci
CA2787844C (fr)	2010-02-03	2019-08-27	Biomarin Pharmaceutical Inc.	Inhibiteurs a base de dihydropyridophtalazinone de la poly(adp-ribose) polymerase (parp) utilisables dans le cadre du traitement de maladies associees a un deficit en pten
MX340319B (es)	2010-02-08	2016-07-06	Medivation Technologies Inc	Procesos para sintetizar derivados de dihidropiridoftalazinona.
WO2011141909A2 (fr)	2010-05-10	2011-11-17	Radikal Therapeutics Inc.	Dérivés d'acide lipoïque et de nitroxide et leurs utilisations
CN103282365B (zh)	2010-10-21	2017-12-29	麦迪韦逊科技有限公司	结晶的(8S,9R)‑5‑氟‑8‑(4‑氟苯基)‑9‑(1‑甲基‑1H‑1,2,4‑三唑‑5‑基)‑8,9‑二氢‑2H‑吡啶并[4,3,2‑de]酞嗪‑3(7H)‑酮甲苯磺酸盐
WO2012074840A2 (fr) *	2010-11-22	2012-06-07	The General Hospital Corporation	Compositions et procédés d'imagerie in vivo
CN103130723B (zh)	2011-11-30	2015-01-14	成都地奥制药集团有限公司	一种多聚(adp-核糖)聚合酶抑制剂
CN103325380B (zh)	2012-03-23	2017-09-12	杜比实验室特许公司	用于信号增强的增益后处理
US10722484B2 (en)	2016-03-09	2020-07-28	K-Gen, Inc.	Methods of cancer treatment
WO2018022851A1 (fr)	2016-07-28	2018-02-01	Mitobridge, Inc.	Méthode de traitement de lésions rénales aiguës.
AU2017355402A1 (en)	2016-11-02	2019-05-30	Health Research, Inc.	Combination treatment with antibody-drug conjugates and PARP inhibitors
CN117897380A (zh) *	2021-08-17	2024-04-16	益方生物科技(上海)股份有限公司	哒嗪酮或吡啶酮化合物、其制备方法和用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS58116471A (ja) *	1981-12-29	1983-07-11	Nippon Kayaku Co Ltd	４−ヒドロキシメチル−１−フタラゾンエステル誘導体およびその塩
US4939140A (en) *	1985-11-07	1990-07-03	Pfizer Inc.	Heterocyclic oxophthalazinyl acetic acids
EP0722936B1 (fr)	1994-08-09	2004-05-19	Eisai Co., Ltd.	Compose de pyridazine condense
US6635642B1 (en) *	1997-09-03	2003-10-21	Guilford Pharmaceuticals Inc.	PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
WO1998045292A1 (fr) *	1997-12-02	1998-10-15	Dr. Reddy's Research Foundation	Derives de thiazolidinedione et d'oxazolidinedione ayant des proprietes antidiabetiques, hypolipidemiques et antihypertenseurs
CO5070700A1 (es)	1998-06-05	2001-08-28	Basf Ag	Genes novedosos de (adp-ribosa) polimerasa
ITMI981671A1 (it)	1998-07-21	2000-01-21	Zambon Spa	Derivati ftalazinici inibitori della fosfodisterasi 4
ITMI981670A1 (it) *	1998-07-21	2000-01-21	Zambon Spa	Derivati ftalazinici inibitori della fosfodiesterasi 4

1999
- 1999-05-11 DE DE19921567A patent/DE19921567A1/de not_active Withdrawn
2000
- 2000-05-03 US US09/959,404 patent/US6903098B1/en not_active Expired - Fee Related
- 2000-05-03 CN CN00808074A patent/CN1399573A/zh active Pending
- 2000-05-03 KR KR1020017014342A patent/KR20020000642A/ko not_active Ceased
- 2000-05-03 HU HU0202477A patent/HUP0202477A3/hu unknown
- 2000-05-03 JP JP2000616761A patent/JP2003502286A/ja active Pending
- 2000-05-03 TR TR2001/03236T patent/TR200103236T2/xx unknown
- 2000-05-03 AU AU50640/00A patent/AU5064000A/en not_active Abandoned
- 2000-05-03 WO PCT/EP2000/003967 patent/WO2000067734A2/fr not_active Ceased
- 2000-05-03 SK SK1595-2001A patent/SK286676B6/sk not_active IP Right Cessation
- 2000-05-03 CZ CZ20014038A patent/CZ20014038A3/cs unknown
- 2000-05-03 DE DE50014190T patent/DE50014190D1/de not_active Expired - Lifetime
- 2000-05-03 EP EP00934980A patent/EP1231982B1/fr not_active Expired - Lifetime
- 2000-05-03 BR BR0010428-0A patent/BR0010428A/pt not_active IP Right Cessation
- 2000-05-03 CA CA002372704A patent/CA2372704A1/fr not_active Abandoned
- 2000-05-03 AT AT00934980T patent/ATE357272T1/de not_active IP Right Cessation
- 2000-05-03 PL PL00352150A patent/PL352150A1/xx not_active Application Discontinuation
- 2000-05-03 ES ES00934980T patent/ES2284499T3/es not_active Expired - Lifetime
- 2000-05-03 IL IL14614800A patent/IL146148A0/xx unknown
2001
- 2001-10-26 BG BG106056A patent/BG106056A/xx unknown
- 2001-11-08 NO NO20015462A patent/NO20015462L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
NO20015462D0 (no)	2001-11-08
CN1399573A (zh)	2003-02-26
HUP0202477A2 (hu)	2002-12-28
AU5064000A (en)	2000-11-21
WO2000067734A3 (fr)	2002-06-20
CA2372704A1 (fr)	2000-11-16
TR200103236T2 (tr)	2004-08-23
DE50014190D1 (de)	2007-05-03
ES2284499T3 (es)	2007-11-16
BR0010428A (pt)	2002-04-30
EP1231982A2 (fr)	2002-08-21
EP1231982B1 (fr)	2007-03-21
CZ20014038A3 (cs)	2002-06-12
PL352150A1 (en)	2003-07-28
SK286676B6 (sk)	2009-03-05
ATE357272T1 (de)	2007-04-15
US6903098B1 (en)	2005-06-07
IL146148A0 (en)	2002-07-25
JP2003502286A (ja)	2003-01-21
BG106056A (en)	2002-06-28
DE19921567A1 (de)	2000-11-16
HUP0202477A3 (en)	2003-02-28
SK15952001A3 (sk)	2002-08-06
KR20020000642A (ko)	2002-01-05
WO2000067734A2 (fr)	2000-11-16

Legal Events

Date	Code	Title	Description
2004-01-19	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20015462D0 (no)	2001-11-08	Anvendelse av fthalazinderivater
TR200103221T2 (tr)	2002-04-22	Heterosiklik olarak ikame edilmiş benzimidazoller, bunların üretimi ve uygulanması
ATE355278T1 (de)	2006-03-15	Isochinolinon derivate als parp inhibitoren
MY135732A (en)	2008-06-30	5,6-trimethylenepyrimidin - 4 - one compounds
TR200101400T2 (tr)	2001-11-21	2-Fenilbenzimidazoller ve 2-fenilindoller, hazırlanmaları ve kullanımları
EP1144373A3 (fr)	2002-01-02	Inhibiteurs de la serine protease
ATE238415T1 (de)	2003-05-15	Feste phytase-zusammensetzungen
ZA991975B (en)	1999-09-27	Enzyme inhibitors.
EP1818396A3 (fr)	2007-12-19	Variantes d'Alpha Amylasa
WO2001066564A3 (fr)	2002-01-03	Inhibiteurs de gamma-sécrétase
AU2352201A (en)	2001-07-16	Improved lysosomal enzymes and lysosomal enzyme activators
EP1224266A4 (fr)	2003-05-28	Enzymes a voie de ciblage lysosomial
WO2005058798A3 (fr)	2006-02-16	Composes possedant un cytochrome selectif p450rai-1 ou une activite inhibitrice de cytochrome selectif p450rai-2 et techniques permettant d'obtenir ces composes
WO1999015129A3 (fr)	2001-07-26	INHIBITEURS SELECTIFS DE cPLA¿2?
MXPA04004372A (es)	2004-08-11	Derivados heterociclicos de glicinamida y su uso medico.
WO2001070204A3 (fr)	2002-08-01	Inhibiteurs a selectivite elevee de l'activateur de type urokinase du plasminogene
PL350920A1 (en)	2003-02-10	Substituted 3-cyano-[1.7], [1.5], and [1.8]-naphthyridine inhibitors of tyrosine kinases
WO2002044360A3 (fr)	2002-12-19	Arginine deiminase modifiee
WO2001066144A3 (fr)	2002-03-28	Therapie d'association de medicaments
GB9621814D0 (en)	1996-12-11	Metalloproteinase inhibitors
EP1240902A4 (fr)	2009-08-26	Agents ameliorant le stress du au carbonyle
WO2001060986A3 (fr)	2002-02-28	Enzymes hydrolases a activite selective
BG105252A (en)	2001-12-29	Isoquinolines as urokinase inhibitors
HK1052315A1 (zh)	2003-09-11	抗血栓形成合成物
PT1196606E (pt)	2005-03-31	Enzima litica